Evaluation of multiple protein profiles from treated xenograft tumor models identifies a marker panel for FFPE tissue analysis with reverse phase protein arrays
Background: Molecular profiling of patient tumors today uses high throughput genome and transcriptome technologies, yet proteins and especially their functions, on which drugs can act, are poorly predicted. Proteomic approaches like reverse phase protein arrays (RPPA) have demonstrated in several st...
Gespeichert in:
Veröffentlicht in: | European journal of cancer (1990) 2016-12, Vol.69, p.S112-S112 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | S112 |
---|---|
container_issue | |
container_start_page | S112 |
container_title | European journal of cancer (1990) |
container_volume | 69 |
creator | Bader, S Zajac, M Friess, T Ruge, E Rieder, N Gierke, B Heubach, Y Thomas, M Pawlak, M |
description | Background: Molecular profiling of patient tumors today uses high throughput genome and transcriptome technologies, yet proteins and especially their functions, on which drugs can act, are poorly predicted. Proteomic approaches like reverse phase protein arrays (RPPA) have demonstrated in several studies that signaling pathway profiling with up to hundreds of samples and proteins in parallel can add valuable information (i) providing multiple marker patterns from small amounts of tissue, and (ii) providing biological answers: Are pathways active downstream of a driver mutation? Will drug treatment be effective? What are the underlying mechanisms? Can we identify predictive marker proteins? So far. a lot of RPPA data have been generated from fresh frozen (FF) tissues, however formalin fixation and paraffin embedding (FFPE) is the standard method for tissue preservation in the clinic. Here we performed RPPA to measure tumor profiles in treated FF and FFPE xenograft tumors to identify a marker panel suited for the analysis of clinical FFPE tissue samples. Material and Methods: Protein lysates were prepared from matched FF and FFPE tissues specimen of three different xenograft tumor models. Tumor material was taken from randomized mice, untreated (vehicle control) and treated with either anti-Her3 or bispecific anti-IGF1R/EGFR monoclonal antibodies. Straight after collection, the individual tumors from each study animal were divided in half--one half was immediately snap frozen and the remaining part fixed in formalin and paraffin embedded (n = 3 mice per treatment group). Protein lysates were analyzed via RPPA as one cohort in parallel applying direct, sensitive and quantitative fluorescence read-out immunoassays. Results: In total, protein extracts from matched FF and FFPE tumor tissues from 20 xenograft individual tumors (40 samples) were evaluated by RPPA using a panel of 300 markers. The markers covered a broad range of signaling pathways and had been pre-validated up-front in the FF tissue type. Overall a list of top 60 markers was identified that significantly correlated between the FF and FFPE tissue profiles (p < 0.01). No relationship between the cellular location (membrane, cytoplasm or nucleus) of the correlating markers was apparent, and both phosphorylated and non-phosphorylated proteins were represented. Conclusion: The data demonstrate that using appropriate assay reagents, RPPA analyses from FFPE tissue is well feasible and can provide biologi |
doi_str_mv | 10.1016/S0959-8049(16)32933-1 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2037440339</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0959804916329331</els_id><sourcerecordid>2037440339</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1299-48b0c702dadb2ab98ff7db46b866394cb5af1746668514bf42a323a56954b5a3</originalsourceid><addsrcrecordid>eNpFkd1u1DAQhSMEEkvhEZAscQMXaf0XJ75BQtUurVSpSPTemiRj6taJF9vZsm_Do-LdrcrVaDTfnGPPqaqPjJ4zytTFT6obXXdU6s9MfRFcC1GzV9WKda2uadfw19XqBXlbvUvpgVLadpKuqr_rHfgFsgszCZZMi89u65FsY8jo5kO1zmMiNoaJ5IiQcSR_cA6_IthM8jKFSKYwok_EjThnZ13BgUwQHzGSLczoiS3QZvNjTbJLaUECM_h9cok8uXxPIu4wpmJ6D-m_NcQI-_S-emPBJ_zwXM-qu8367vKqvrn9fn357aYeGNe6ll1Ph5byEcaeQ687a9uxl6rvlBJaDn0DlrVSKdU1TPZWchBcQKN0I8tMnFWfTrLF_feCKZuHsMTyymQ4Fa2UVAhdqOZEDTGkFNGabXTlo3vDqDlkYY5ZmMOhTemOWRhW9r6e9sqVcOcwmsG72Q3gH3GP6cWKmcQNPYkcNJg6KjDxD_yUlUY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2037440339</pqid></control><display><type>article</type><title>Evaluation of multiple protein profiles from treated xenograft tumor models identifies a marker panel for FFPE tissue analysis with reverse phase protein arrays</title><source>Elsevier ScienceDirect Journals</source><creator>Bader, S ; Zajac, M ; Friess, T ; Ruge, E ; Rieder, N ; Gierke, B ; Heubach, Y ; Thomas, M ; Pawlak, M</creator><creatorcontrib>Bader, S ; Zajac, M ; Friess, T ; Ruge, E ; Rieder, N ; Gierke, B ; Heubach, Y ; Thomas, M ; Pawlak, M</creatorcontrib><description>Background: Molecular profiling of patient tumors today uses high throughput genome and transcriptome technologies, yet proteins and especially their functions, on which drugs can act, are poorly predicted. Proteomic approaches like reverse phase protein arrays (RPPA) have demonstrated in several studies that signaling pathway profiling with up to hundreds of samples and proteins in parallel can add valuable information (i) providing multiple marker patterns from small amounts of tissue, and (ii) providing biological answers: Are pathways active downstream of a driver mutation? Will drug treatment be effective? What are the underlying mechanisms? Can we identify predictive marker proteins? So far. a lot of RPPA data have been generated from fresh frozen (FF) tissues, however formalin fixation and paraffin embedding (FFPE) is the standard method for tissue preservation in the clinic. Here we performed RPPA to measure tumor profiles in treated FF and FFPE xenograft tumors to identify a marker panel suited for the analysis of clinical FFPE tissue samples. Material and Methods: Protein lysates were prepared from matched FF and FFPE tissues specimen of three different xenograft tumor models. Tumor material was taken from randomized mice, untreated (vehicle control) and treated with either anti-Her3 or bispecific anti-IGF1R/EGFR monoclonal antibodies. Straight after collection, the individual tumors from each study animal were divided in half--one half was immediately snap frozen and the remaining part fixed in formalin and paraffin embedded (n = 3 mice per treatment group). Protein lysates were analyzed via RPPA as one cohort in parallel applying direct, sensitive and quantitative fluorescence read-out immunoassays. Results: In total, protein extracts from matched FF and FFPE tumor tissues from 20 xenograft individual tumors (40 samples) were evaluated by RPPA using a panel of 300 markers. The markers covered a broad range of signaling pathways and had been pre-validated up-front in the FF tissue type. Overall a list of top 60 markers was identified that significantly correlated between the FF and FFPE tissue profiles (p < 0.01). No relationship between the cellular location (membrane, cytoplasm or nucleus) of the correlating markers was apparent, and both phosphorylated and non-phosphorylated proteins were represented. Conclusion: The data demonstrate that using appropriate assay reagents, RPPA analyses from FFPE tissue is well feasible and can provide biologically significant information for a large panel of proteins using minute amounts of tissue. The identified panel of markers may be useful for pharmacodynamic studies of drug effect bridging pre-clinical to clinical results. The approach may be a versatile tool in clinical research, translational medicine and pharmaceutical drug development to stratify patient tumours and to predict drug response.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/S0959-8049(16)32933-1</identifier><language>eng</language><publisher>Oxford: Elsevier Science Ltd</publisher><subject>Animal models ; Bispecific antibodies ; Cytoplasm ; Drug development ; Embedding ; Epidermal growth factor receptors ; Feasibility studies ; Fluorescence ; Formaldehyde ; Gene expression ; Genomes ; Hematology, Oncology and Palliative Medicine ; Immunoassays ; Lysates ; Markers ; Mathematical models ; Mice ; Molecular chains ; Monoclonal antibodies ; Nuclei ; Nuclei (cytology) ; Paraffin ; Patients ; Pharmacodynamics ; Pharmacology ; Preservation ; Protein arrays ; Proteins ; Proteomics ; Reagents ; Signal transduction ; Signaling ; Tissue analysis ; Tissues ; Tumors ; Xenografts ; Xenotransplantation</subject><ispartof>European journal of cancer (1990), 2016-12, Vol.69, p.S112-S112</ispartof><rights>Elsevier Ltd</rights><rights>Copyright Elsevier Science Ltd. Dec 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Bader, S</creatorcontrib><creatorcontrib>Zajac, M</creatorcontrib><creatorcontrib>Friess, T</creatorcontrib><creatorcontrib>Ruge, E</creatorcontrib><creatorcontrib>Rieder, N</creatorcontrib><creatorcontrib>Gierke, B</creatorcontrib><creatorcontrib>Heubach, Y</creatorcontrib><creatorcontrib>Thomas, M</creatorcontrib><creatorcontrib>Pawlak, M</creatorcontrib><title>Evaluation of multiple protein profiles from treated xenograft tumor models identifies a marker panel for FFPE tissue analysis with reverse phase protein arrays</title><title>European journal of cancer (1990)</title><description>Background: Molecular profiling of patient tumors today uses high throughput genome and transcriptome technologies, yet proteins and especially their functions, on which drugs can act, are poorly predicted. Proteomic approaches like reverse phase protein arrays (RPPA) have demonstrated in several studies that signaling pathway profiling with up to hundreds of samples and proteins in parallel can add valuable information (i) providing multiple marker patterns from small amounts of tissue, and (ii) providing biological answers: Are pathways active downstream of a driver mutation? Will drug treatment be effective? What are the underlying mechanisms? Can we identify predictive marker proteins? So far. a lot of RPPA data have been generated from fresh frozen (FF) tissues, however formalin fixation and paraffin embedding (FFPE) is the standard method for tissue preservation in the clinic. Here we performed RPPA to measure tumor profiles in treated FF and FFPE xenograft tumors to identify a marker panel suited for the analysis of clinical FFPE tissue samples. Material and Methods: Protein lysates were prepared from matched FF and FFPE tissues specimen of three different xenograft tumor models. Tumor material was taken from randomized mice, untreated (vehicle control) and treated with either anti-Her3 or bispecific anti-IGF1R/EGFR monoclonal antibodies. Straight after collection, the individual tumors from each study animal were divided in half--one half was immediately snap frozen and the remaining part fixed in formalin and paraffin embedded (n = 3 mice per treatment group). Protein lysates were analyzed via RPPA as one cohort in parallel applying direct, sensitive and quantitative fluorescence read-out immunoassays. Results: In total, protein extracts from matched FF and FFPE tumor tissues from 20 xenograft individual tumors (40 samples) were evaluated by RPPA using a panel of 300 markers. The markers covered a broad range of signaling pathways and had been pre-validated up-front in the FF tissue type. Overall a list of top 60 markers was identified that significantly correlated between the FF and FFPE tissue profiles (p < 0.01). No relationship between the cellular location (membrane, cytoplasm or nucleus) of the correlating markers was apparent, and both phosphorylated and non-phosphorylated proteins were represented. Conclusion: The data demonstrate that using appropriate assay reagents, RPPA analyses from FFPE tissue is well feasible and can provide biologically significant information for a large panel of proteins using minute amounts of tissue. The identified panel of markers may be useful for pharmacodynamic studies of drug effect bridging pre-clinical to clinical results. The approach may be a versatile tool in clinical research, translational medicine and pharmaceutical drug development to stratify patient tumours and to predict drug response.</description><subject>Animal models</subject><subject>Bispecific antibodies</subject><subject>Cytoplasm</subject><subject>Drug development</subject><subject>Embedding</subject><subject>Epidermal growth factor receptors</subject><subject>Feasibility studies</subject><subject>Fluorescence</subject><subject>Formaldehyde</subject><subject>Gene expression</subject><subject>Genomes</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Immunoassays</subject><subject>Lysates</subject><subject>Markers</subject><subject>Mathematical models</subject><subject>Mice</subject><subject>Molecular chains</subject><subject>Monoclonal antibodies</subject><subject>Nuclei</subject><subject>Nuclei (cytology)</subject><subject>Paraffin</subject><subject>Patients</subject><subject>Pharmacodynamics</subject><subject>Pharmacology</subject><subject>Preservation</subject><subject>Protein arrays</subject><subject>Proteins</subject><subject>Proteomics</subject><subject>Reagents</subject><subject>Signal transduction</subject><subject>Signaling</subject><subject>Tissue analysis</subject><subject>Tissues</subject><subject>Tumors</subject><subject>Xenografts</subject><subject>Xenotransplantation</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpFkd1u1DAQhSMEEkvhEZAscQMXaf0XJ75BQtUurVSpSPTemiRj6taJF9vZsm_Do-LdrcrVaDTfnGPPqaqPjJ4zytTFT6obXXdU6s9MfRFcC1GzV9WKda2uadfw19XqBXlbvUvpgVLadpKuqr_rHfgFsgszCZZMi89u65FsY8jo5kO1zmMiNoaJ5IiQcSR_cA6_IthM8jKFSKYwok_EjThnZ13BgUwQHzGSLczoiS3QZvNjTbJLaUECM_h9cok8uXxPIu4wpmJ6D-m_NcQI-_S-emPBJ_zwXM-qu8367vKqvrn9fn357aYeGNe6ll1Ph5byEcaeQ687a9uxl6rvlBJaDn0DlrVSKdU1TPZWchBcQKN0I8tMnFWfTrLF_feCKZuHsMTyymQ4Fa2UVAhdqOZEDTGkFNGabXTlo3vDqDlkYY5ZmMOhTemOWRhW9r6e9sqVcOcwmsG72Q3gH3GP6cWKmcQNPYkcNJg6KjDxD_yUlUY</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Bader, S</creator><creator>Zajac, M</creator><creator>Friess, T</creator><creator>Ruge, E</creator><creator>Rieder, N</creator><creator>Gierke, B</creator><creator>Heubach, Y</creator><creator>Thomas, M</creator><creator>Pawlak, M</creator><general>Elsevier Science Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20161201</creationdate><title>Evaluation of multiple protein profiles from treated xenograft tumor models identifies a marker panel for FFPE tissue analysis with reverse phase protein arrays</title><author>Bader, S ; Zajac, M ; Friess, T ; Ruge, E ; Rieder, N ; Gierke, B ; Heubach, Y ; Thomas, M ; Pawlak, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1299-48b0c702dadb2ab98ff7db46b866394cb5af1746668514bf42a323a56954b5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animal models</topic><topic>Bispecific antibodies</topic><topic>Cytoplasm</topic><topic>Drug development</topic><topic>Embedding</topic><topic>Epidermal growth factor receptors</topic><topic>Feasibility studies</topic><topic>Fluorescence</topic><topic>Formaldehyde</topic><topic>Gene expression</topic><topic>Genomes</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Immunoassays</topic><topic>Lysates</topic><topic>Markers</topic><topic>Mathematical models</topic><topic>Mice</topic><topic>Molecular chains</topic><topic>Monoclonal antibodies</topic><topic>Nuclei</topic><topic>Nuclei (cytology)</topic><topic>Paraffin</topic><topic>Patients</topic><topic>Pharmacodynamics</topic><topic>Pharmacology</topic><topic>Preservation</topic><topic>Protein arrays</topic><topic>Proteins</topic><topic>Proteomics</topic><topic>Reagents</topic><topic>Signal transduction</topic><topic>Signaling</topic><topic>Tissue analysis</topic><topic>Tissues</topic><topic>Tumors</topic><topic>Xenografts</topic><topic>Xenotransplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bader, S</creatorcontrib><creatorcontrib>Zajac, M</creatorcontrib><creatorcontrib>Friess, T</creatorcontrib><creatorcontrib>Ruge, E</creatorcontrib><creatorcontrib>Rieder, N</creatorcontrib><creatorcontrib>Gierke, B</creatorcontrib><creatorcontrib>Heubach, Y</creatorcontrib><creatorcontrib>Thomas, M</creatorcontrib><creatorcontrib>Pawlak, M</creatorcontrib><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bader, S</au><au>Zajac, M</au><au>Friess, T</au><au>Ruge, E</au><au>Rieder, N</au><au>Gierke, B</au><au>Heubach, Y</au><au>Thomas, M</au><au>Pawlak, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of multiple protein profiles from treated xenograft tumor models identifies a marker panel for FFPE tissue analysis with reverse phase protein arrays</atitle><jtitle>European journal of cancer (1990)</jtitle><date>2016-12-01</date><risdate>2016</risdate><volume>69</volume><spage>S112</spage><epage>S112</epage><pages>S112-S112</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>Background: Molecular profiling of patient tumors today uses high throughput genome and transcriptome technologies, yet proteins and especially their functions, on which drugs can act, are poorly predicted. Proteomic approaches like reverse phase protein arrays (RPPA) have demonstrated in several studies that signaling pathway profiling with up to hundreds of samples and proteins in parallel can add valuable information (i) providing multiple marker patterns from small amounts of tissue, and (ii) providing biological answers: Are pathways active downstream of a driver mutation? Will drug treatment be effective? What are the underlying mechanisms? Can we identify predictive marker proteins? So far. a lot of RPPA data have been generated from fresh frozen (FF) tissues, however formalin fixation and paraffin embedding (FFPE) is the standard method for tissue preservation in the clinic. Here we performed RPPA to measure tumor profiles in treated FF and FFPE xenograft tumors to identify a marker panel suited for the analysis of clinical FFPE tissue samples. Material and Methods: Protein lysates were prepared from matched FF and FFPE tissues specimen of three different xenograft tumor models. Tumor material was taken from randomized mice, untreated (vehicle control) and treated with either anti-Her3 or bispecific anti-IGF1R/EGFR monoclonal antibodies. Straight after collection, the individual tumors from each study animal were divided in half--one half was immediately snap frozen and the remaining part fixed in formalin and paraffin embedded (n = 3 mice per treatment group). Protein lysates were analyzed via RPPA as one cohort in parallel applying direct, sensitive and quantitative fluorescence read-out immunoassays. Results: In total, protein extracts from matched FF and FFPE tumor tissues from 20 xenograft individual tumors (40 samples) were evaluated by RPPA using a panel of 300 markers. The markers covered a broad range of signaling pathways and had been pre-validated up-front in the FF tissue type. Overall a list of top 60 markers was identified that significantly correlated between the FF and FFPE tissue profiles (p < 0.01). No relationship between the cellular location (membrane, cytoplasm or nucleus) of the correlating markers was apparent, and both phosphorylated and non-phosphorylated proteins were represented. Conclusion: The data demonstrate that using appropriate assay reagents, RPPA analyses from FFPE tissue is well feasible and can provide biologically significant information for a large panel of proteins using minute amounts of tissue. The identified panel of markers may be useful for pharmacodynamic studies of drug effect bridging pre-clinical to clinical results. The approach may be a versatile tool in clinical research, translational medicine and pharmaceutical drug development to stratify patient tumours and to predict drug response.</abstract><cop>Oxford</cop><pub>Elsevier Science Ltd</pub><doi>10.1016/S0959-8049(16)32933-1</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0959-8049 |
ispartof | European journal of cancer (1990), 2016-12, Vol.69, p.S112-S112 |
issn | 0959-8049 1879-0852 |
language | eng |
recordid | cdi_proquest_journals_2037440339 |
source | Elsevier ScienceDirect Journals |
subjects | Animal models Bispecific antibodies Cytoplasm Drug development Embedding Epidermal growth factor receptors Feasibility studies Fluorescence Formaldehyde Gene expression Genomes Hematology, Oncology and Palliative Medicine Immunoassays Lysates Markers Mathematical models Mice Molecular chains Monoclonal antibodies Nuclei Nuclei (cytology) Paraffin Patients Pharmacodynamics Pharmacology Preservation Protein arrays Proteins Proteomics Reagents Signal transduction Signaling Tissue analysis Tissues Tumors Xenografts Xenotransplantation |
title | Evaluation of multiple protein profiles from treated xenograft tumor models identifies a marker panel for FFPE tissue analysis with reverse phase protein arrays |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T12%3A52%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20multiple%20protein%20profiles%20from%20treated%20xenograft%20tumor%20models%20identifies%20a%20marker%20panel%20for%20FFPE%20tissue%20analysis%20with%20reverse%20phase%20protein%20arrays&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Bader,%20S&rft.date=2016-12-01&rft.volume=69&rft.spage=S112&rft.epage=S112&rft.pages=S112-S112&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/S0959-8049(16)32933-1&rft_dat=%3Cproquest_cross%3E2037440339%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2037440339&rft_id=info:pmid/&rft_els_id=1_s2_0_S0959804916329331&rfr_iscdi=true |